Spinocerebellar ataxia type-13

From WikiMD's Medical Encyclopedia

(Redirected from SCA13)

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics

Spinocerebellar ataxia type 13
Synonyms SCA13
Pronounce N/A
Specialty N/A
Symptoms N/A
Complications N/A
Onset Childhood or adulthood
Duration Chronic
Types N/A
Causes Genetic mutation in the KCNC3 gene
Risks Family history
Diagnosis Genetic testing, neurological examination
Differential diagnosis N/A
Prevention N/A
Treatment Symptomatic treatment, physical therapy, occupational therapy
Medication N/A
Prognosis Variable prognosis
Frequency Rare
Deaths N/A


Spinocerebellar ataxia type 13 (SCA13) is a rare, genetic condition that affects the cerebellum and causes progressive problems with movement. It is one of several types of spinocerebellar ataxia (SCA), which are all characterized by degenerative changes in the part of the brain related to the control of movement.

Symptoms[edit]

The symptoms of SCA13 can vary widely, even among members of the same family. They typically include poor coordination of movements (ataxia), difficulty with balance, and problems with speech (dysarthria). Some people may also have mild intellectual disability or learning problems.

Causes[edit]

SCA13 is caused by mutations in the KCNC3 gene. This gene provides instructions for making a protein that is involved in sending signals in nerve cells, particularly in the cerebellum. Mutations in the KCNC3 gene disrupt these signals, leading to the symptoms of SCA13.

Diagnosis[edit]

Diagnosis of SCA13 is based on the presence of characteristic neurological symptoms, a family history of the disease, and genetic testing. Genetic testing can confirm a diagnosis by identifying a mutation in the KCNC3 gene.

Treatment[edit]

There is currently no cure for SCA13. Treatment is focused on managing symptoms and may include physical therapy, speech therapy, and medications to control spasticity.

Prognosis[edit]

The prognosis for people with SCA13 varies. Some people may have mild symptoms and a normal lifespan, while others may have severe symptoms and a shortened lifespan.

See also[edit]

This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.